Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that GlaxoSmithKline's tamsulosin/dutasteride is positioned to overtake Avodart, also from GlaxoSmithKline, as the clinical gold standard for the treatment of benign prostatic hyperplasia. Tamsulosin/dutasteride has competitive advantages in efficacy, safety, tolerability and delivery. This novel combination agent will earn a 10% patient share in the U.S. benign prostatic hyperplasia market in 2011.

According to the new report entitled: Benign Prostatic Hyperplasia: Subtle Improvements over Current Therapies Would Mean Palpable Opportunity for Drug Developers, a benign prostatic hyperplasia drug treatment with a lower incidence of sexual side effects than that of tamsulosin (Boehringer Ingelheim's Flomax, generics) would earn a 40% patient share in benign prostatic hyperplasia. Urologists indicate the goal for treating benign prostatic hyperplasia patients with drug therapy is to relieve urinary symptoms in order to maintain a high level of quality of life for patients.

"Urologists are generally not willing to accept trade-offs in efficacy, safety and tolerability or delivery when considering a benign prostatic hyperplasia drug with a lower incidence of sexual side effects than Flomax," said Greg Dwyer, analyst at Decision Resources. "Given the high level of satisfaction with currently available medications, it is not surprising that surveyed physicians would have demanding requirements for both the minimal acceptable and major achievement profiles. The goal for many physicians is to relieve symptoms so the patient can maintain a high level of quality of life. Urologists we surveyed overwhelmingly selected 'symptom improvement' as the efficacy measure they consider when considering treatment options."

About the Report

Benign Prostatic Hyperplasia: Subtle Improvements over Current Therapies Would Mean Palpable Opportunity for Drug Developers is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016

View Now